Tag Archive for ‘clinical trials’
Modified FOLFIRINOX is superior to gemcitabine as adjuvant therapy for resected pancreatic cancer: The PRODIGE 24/CCTG PA6 Trial
The study design and findings of the PRODIGE 24/CCTG PA6 Trial are outlined, which showed improved survival with modified FOLFIRINOX for resected pancreatic cancer patients.
The ALCHEMIST CHEMO-IO is a trial for patients with early-stage non-small cell lung cancer (NSCLC) with the potential to change the way patients with resected NSCLC are treated.
A summary of some of the research that evaluates the role of axillary reverse mapping in cancer patients.
Describes the traditional management of desmoid tumors as well as new approaches, including radiation therapy for locally aggressive tumors.
The ACS CRP will offer sessions at Clinical Congress 2019 on the topics of developing clinical trial and decreasing administrative burden associated with those trials.
Clinical trial data are examined to help develop a consensus approach for locally advanced gastric cancer.
Smoking cessation intervention trials examine potential outcome improvements for lung cancer patients.
Atezolizumab in the adjuvant treatment of stage III colon cancer: Can PD-L1 inhibition improve survival?
The study design for the ATOMIC trial (Alliance A021502), a randomized phase III study examining atezolizumab treatment of stage III colon cancer, is described.
Robotic surgery for hepatic neoplasms: Where does it fit in the minimally invasive surgery landscape?
This month’s column identifies prospective clinical trials aimed at clarifying the role of laparoscopic and robotic surgery for hepatic neoplasms.
Because many cases of ductal carcinoma in situ (DCIS) may remain stable without excision, more clinical trials are exploring the role of active surveillance in DCIS management.
The role of precision immunotherapy in treating solid tumors is summarized.
An educational program developed jointly by the ACS CRP and the Society of Surgical Oncology provides surgeons with the tools they need to actively participate in clinical trials
The role of immunotherapy in the treatment of urologic cancers is summarized and the efficacy of novel immunotherapeutics, particularly checkpoint inhibitors, are described, which may hold promise for a wide variety of tumor types.
Gastric cancer is a significant cause of cancer morbidity and mortality in the U.S., with an estimated 26,370 new cases and 10,730 deaths in 2016.1 The incidence of gastric cancer is rising, particularly proximal tumors, and among young (< 40 years old) Caucasians, who have experienced a nearly 70 percent increase in the incidence of […]
The mission of the Dissemination and Implementation Committee—to provide surgeons with practice-changing results of the Alliance and other national clinical trial groups—is summarized.
Decision aids to enhance conversations with minority males entering prostate cancer treatment are described.
Strategies for enhancing junior investigator participation in Alliance programs are highlighted.
Improving rectal cancer outcomes through advocacy, education, and research: The OSTRiCh Consortium and the new NAPRC
Over the last three decades, there has been a significant shift in cancer care from the generalist to the specialist setting. This shift is especially true in surgical oncology, where surgeons specializing in the care of breast cancer, esophageal cancer, and pancreatic cancer have become the norm for many facilities treating cancer patients in the […]
The approach, aims, and eligibility criteria of the NRG Oncology TNT clinical trial are summarized.
This month’s column underscores the importance of clinical trial participation, in particular surgeons who have a demonstrated capability and knowledge in conducting research-related operations.